Add BrightSurf on Google Email

Targeted messaging for return to in-person visits

Researchers found that a single targeted message didn't affect the return to in-person visits within a month, but resulted in a small increase in re-engagement through telemedicine and rescheduling of future visits. The study suggests that alternative communication strategies may be more effective for promoting in-person care.

SourceJAMA Network·JournalJAMA Network Open·DateJun 30, 2021

Gene therapy breakthrough offers hope to children with rare and fatal brain disease

Scientists at UCL GOS ICH and Great Ormond Street Hospital have developed a precision gene therapy that has been shown to relieve defects in DTDS brain cells, potentially offering a cure for the condition. The therapy was tested on laboratory models and mice, showing promising results and paving the way for a clinical trial.

SourceUniversity College London·JournalScience Translational Medicine·DateJun 29, 2021

Clinical trial shows cell therapy improves clinical outcomes in heart failure

A clinical trial conducted at the University of Louisville showed that cell therapy using cells derived from a patient's own bone marrow and heart improved quality of life and reduced major adverse cardiac events. The treatment resulted in a significant reduction in hospitalizations and improved outcomes for patients with heart failure.

SourceUniversity of Louisville·JournalEuropean Journal of Heart Failure·DateJun 14, 2021

A randomised trial comparing imaging-guided PCI with Orsiro vs Xience

The CASTLE study investigated the role of imaging-guided percutaneous cardiac intervention (PCI) in clinical outcomes difference between ultra-thin strut biodegradable polymer sirolimus-eluting stent (Orsiro) and durable polymer everolimus-eluting stents (Xience). The results show no significant differences in target lesion failure rat...

SourcePCR·DateMay 18, 2021

Clinical trial suggests convalescent plasma may improve survival with severe COVID-19

A randomized double-blind controlled trial of convalescent plasma for adults hospitalized with severe COVID-19 found mortality at 28 days in the treatment arm was half the rate seen in the control arm. However, treatment was not associated with other improvements in clinical status among patients.

SourceColumbia University's Mailman School of Public Health·JournalJournal of Clinical Investigation·DateMay 17, 2021

Rivaroxaban reduces first and total ischemic events in patients with peripheral artery disease

The study found that rivaroxaban significantly reduced the occurrence of total severe events in patients with symptomatic peripheral artery disease who underwent lower extremity revascularization. The treatment also showed a 12.5% absolute reduction in risk for adverse events in this high-risk population.

SourceAmerican College of Cardiology·JournalJournal of the American College of Cardiology·DateMay 16, 2021

Study finds people of color more likely to participate in cancer clinical trials

A new study from the University of Missouri School of Medicine found that people of color, those with a higher income, and younger individuals are more likely to participate in cancer clinical trials. The analysis of 20,053 respondents showed an average overall clinical trial participation rate of 6.51%, with significant differences in...

SourceUniversity of Missouri-Columbia·JournalContemporary Clinical Trials Communications·DateApr 28, 2021